Literature DB >> 9780137

Urinary excretion half-life of 11-nor-9-carboxy-delta9-tetrahydrocannabinol in humans.

M A Huestis1, E J Cone.   

Abstract

The excretion of marijuana metabolites occurs over an extended period of time, yet few studies have been designed for accurate estimation of excretion half-lives. The authors monitored excretion of the primary urinary metabolite of marijuana, 11-nor-9-carboxy-delta9-tetrahydrocannabinol (THCCOOH), by gas chromatography-mass spectrometry in a controlled clinical study of marijuana smoking that included measurement of the drug in each urine void collected during the 3-week study. Terminal excretion half-lives of THCCOOH were determined in six healthy male subjects with histories of marijuana smoking; the study was conducted on the clinical research unit of a major medical institution. Subjects smoked a single marijuana cigarette (placebo, 1.75% or 3.55% THC) each week. Urine specimens (N=953) were analyzed under blind conditions for THCCOOH by gas chromatography-mass spectrometry. Mean+/-SEM half-lives calculated by the amount remaining to be excreted method after the low and high doses were 31.5+/-1.0 hours (range, 28.4 to 35.3 hours) and 28.6+/-1.5 hours (range, 24.9 to 34.5 hours), respectively, when a 7-day monitoring period was used. The amounts of THCCOOH excreted over a 7-day period were 93.9 +/-24.5 microg (range, 34.6 to 171.6 microg) and 197.4+/-33.6 microg after the low- and high-dose sessions. Longer half-lives, 44.3 to 59.9 hours, were obtained with a 14-day sample collection. This study documents the prolonged excretion of THCCOOH in urine and emphasizes the importance of study design in the precise estimation of terminal excretion half-lives. A sensitive analytical method and a prolonged specimen collection period are important study considerations in the monitoring of marijuana excretion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9780137     DOI: 10.1097/00007691-199810000-00021

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  19 in total

Review 1.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 2.  Cannabis in sport: anti-doping perspective.

Authors:  Marilyn A Huestis; Irene Mazzoni; Olivier Rabin
Journal:  Sports Med       Date:  2011-11-01       Impact factor: 11.136

3.  Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence.

Authors:  Randi Melissa Schuster; Kevin Potter; Ryan Vandrey; Maya Hareli; Jodi Gilman; David Schoenfeld; A Eden Evins
Journal:  J Psychopharmacol       Date:  2019-09-19       Impact factor: 4.153

4.  The influence of recency of use on fMRI response during spatial working memory in adolescent marijuana users.

Authors:  Alecia Dager Schweinsburg; Brian C Schweinsburg; Krista Lisdahl Medina; Tim McQueeny; Sandra A Brown; Susan F Tapert
Journal:  J Psychoactive Drugs       Date:  2010-09

5.  Cannabis use and work-related injuries: a cross-sectional analysis.

Authors:  J C Zhang; N Carnide; L Holness; P Cram
Journal:  Occup Med (Lond)       Date:  2020-12-12       Impact factor: 1.611

6.  Quantitative biochemical screening for marijuana use and concordance with tobacco use in urban adolescents.

Authors:  Neal Benowitz; Natalie Nardone; Gideon St Helen; Newton Addo; Peyton Jacob; Evangelia Liakoni; Shonul Jain; Shirin Hooshfar; Kara Lynch
Journal:  Drug Alcohol Depend       Date:  2019-09-25       Impact factor: 4.492

7.  Quantification and comparison of marijuana smoking practices: blunts, joints, and pipes.

Authors:  John J Mariani; Daniel Brooks; Margaret Haney; Frances R Levin
Journal:  Drug Alcohol Depend       Date:  2010-09-21       Impact factor: 4.492

8.  Delta-9-tetrahydrocannabinol intoxication is associated with increased prefrontal activation as assessed with functional near-infrared spectroscopy: A report of a potential biomarker of intoxication.

Authors:  Jodi M Gilman; Meryem A Yücel; Gladys N Pachas; Kevin Potter; Nina Levar; Hannah Broos; Eve M Manghis; Randi M Schuster; A Eden Evins
Journal:  Neuroimage       Date:  2019-05-07       Impact factor: 6.556

Review 9.  Pharmacokinetics and pharmacodynamics of cannabinoids.

Authors:  Franjo Grotenhermen
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  Extended urinary Delta9-tetrahydrocannabinol excretion in chronic cannabis users precludes use as a biomarker of new drug exposure.

Authors:  Ross H Lowe; Tsadik T Abraham; William D Darwin; Ronald Herning; Jean Lud Cadet; Marilyn A Huestis
Journal:  Drug Alcohol Depend       Date:  2009-07-23       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.